HCPCS Code J0490: Injection, belimumab, 10 mg

## **J0490 documentation requirements** Clear, complete records support medical necessity, dosing accuracy, and payer compliance. ### **Diagnosis and indication** Record the diagnosis (e.g., systemic lupus erythematosus, active lupus nephritis) and that the patient is autoantibody-positive when applicable, including rationale for treatment selection. ### **Product and dose details** Document the brand/generic, strength, total milligrams (in 10-mg units for J0490), vial size, and that the specific substance used was belimumab. ### **Route, schedule, and technique** Note whether the dose was IV infusion or subcutaneous injection; include dates, start/stop times, and the intravenous infusion technique used for facility claims. ### **Monitoring and safety** Capture vitals, labs, hypersensitivity screening, infection risk, psychiatric screening, vaccination status, and any safety concerns observed or mitigated. ### **Response and plan** Summarize clinical response, adverse effects, and next-dose plan; reference published data or policy criteria when needed to support ongoing therapy.

## **J0490 billing requirements** Accurate billing prevents denials and speeds payment. ### **Unit reporting** Report J0490 per injection, belimumab, 10 mg. Units on the claim must match the dose administered exactly. ### **Administration coding** Select appropriate chemotherapy administration codes when criteria are met (e.g., 96413 for IV infusion, up to 1 hour, single or initial substance). Use 96372 for subcutaneous injection when payer policy directs. ### **Claim elements** Include NDC, lot, expiration, site of care, and narrative drug details. Verify Medicare and commercial requirements for medical necessity and site-of-service. ### **Prior authorization and coverage** Check plan policies for SLE/lupus nephritis indications, dosing, and frequency; some payers reference a Benlysta billing and coding guide for documentation expectations. ### **Pricing and waste** Bill wastage from single-use vials per payer rules (see modifiers). Ensure invoice support is available if requested.

## **J0490 applicable modifiers** Use route and wastage modifiers as required by payer policy: - JA - Intravenous administration: Append when belimumab is given by IV. - JB - Subcutaneous administration: Append when the dose is given subcutaneously. - JW - Drug amount discarded/not administered: Use on a separate line for documented wastage from a single-use vial. - JZ - Zero drug wasted: Append when no wastage occurred from a single-dose container. - 99 - Multiple modifiers (if required): Use only when payer systems require stacking modifiers.

## **Other relevant codes** Clinically related and commonly paired codes include: **- 96413**: Chemotherapy administration, IV infusion; up to 1 hour, single or initial substance (complex/biologic infusion). **- 96415**: Each additional hour of chemotherapy IV infusion (list separately in addition to 96413). **- 96372**: Therapeutic/prophylactic/diagnostic injection; subcutaneous or intramuscular (for office-based subcutaneous injection). **- 96375**: Each additional sequential IV push of a new specific substance/drug (when applicable by policy). **- J3590**: Unclassified biologics (use only if a formulation/setting lacks a unique HCPCS and payer policy directs).